Logo

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Share this
Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Shots:

  • The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s Clinical Infectious Diseases
  • In the P-III study- the therapy was superior in completely resolving signs & symptoms of VVC @10 Day (50.5% vs 28.6%); superior mycological eradication (49.5% vs 19.4%); symptom resolution was sustained & further increased (59.6% vs 44.9%). Post hoc analysis showed similar rates of clinical cure & improvement (54.8% & 63.4%)- respectively
  • In the P-II DOVE study- ibrexafungerp showed similar efficacy to SC @10 Day with sustained efficacy @25 Day follow-up- was well-tolerated

 ­ | Ref: Scynexis | Image: Scynexis

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions